VERV VERVE THERAPEUTICS INC

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York.

A live webcast will be available in the investor section of the company's website at . The webcast will be archived for 30 days following the presentation.

About Verve Therapeutics 

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as pharmacologic targets for lowering low-density lipoprotein cholesterol (“LDL-C”), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.

Investor Contact

Jen Robinson

Verve Therapeutics, Inc.

Media Contact

Ashlea Kosikowski

1AB



EN
01/02/2024

Underlying

VERVVERVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VERVE THERAPEUTICS INC

 PRESS RELEASE
Free
VERV VERVE THERAPEUT...

Verve Therapeutics Announces Pipeline Progress and Reports First Quart...

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketab...

May 14, 2025 1 EN
 PRESS RELEASE
Free
VERV VERVE THERAPEUT...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 13...

May 2, 2025 1 EN
 PRESS RELEASE
Free
VERV VERVE THERAPEUT...

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Ph...

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstra...

April 14, 2025 1 EN
 PRESS RELEASE
Free
VERV VERVE THERAPEUT...

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-...

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company’s novel, in vivo, investigational base ed...

April 11, 2025 1 EN
 PRESS RELEASE
Free
VERV VERVE THERAPEUT...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 5...

April 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch